NO20054095L - Pyridyloksymetyl og benzioksazolazabicyklisk derivater - Google Patents

Pyridyloksymetyl og benzioksazolazabicyklisk derivater

Info

Publication number
NO20054095L
NO20054095L NO20054095A NO20054095A NO20054095L NO 20054095 L NO20054095 L NO 20054095L NO 20054095 A NO20054095 A NO 20054095A NO 20054095 A NO20054095 A NO 20054095A NO 20054095 L NO20054095 L NO 20054095L
Authority
NO
Norway
Prior art keywords
alkoxy
hydrogen
alkyl
disorders
oxygen
Prior art date
Application number
NO20054095A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054095D0 (no
Inventor
Gene Michael Bright
Bishop Wlodecki
Michael Aaron Brodney
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20054095D0 publication Critical patent/NO20054095D0/no
Publication of NO20054095L publication Critical patent/NO20054095L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20054095A 2003-03-12 2005-09-02 Pyridyloksymetyl og benzioksazolazabicyklisk derivater NO20054095L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45392503P 2003-03-12 2003-03-12
PCT/IB2004/000499 WO2004081007A1 (en) 2003-03-12 2004-02-23 Pyridyloxymethyl and benzisoxazole azabicyclic derivatives

Publications (2)

Publication Number Publication Date
NO20054095D0 NO20054095D0 (no) 2005-09-02
NO20054095L true NO20054095L (no) 2005-09-26

Family

ID=32990837

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054095A NO20054095L (no) 2003-03-12 2005-09-02 Pyridyloksymetyl og benzioksazolazabicyklisk derivater

Country Status (30)

Country Link
US (1) US7345038B2 (enExample)
EP (1) EP1608648B1 (enExample)
JP (2) JP3910627B2 (enExample)
KR (2) KR100767854B1 (enExample)
CN (1) CN100389115C (enExample)
AP (1) AP2005003390A0 (enExample)
AR (1) AR043537A1 (enExample)
AU (2) AU2004220327B2 (enExample)
BR (1) BRPI0408248A (enExample)
CA (1) CA2518740C (enExample)
EA (1) EA009527B1 (enExample)
EC (1) ECSP056011A (enExample)
GT (1) GT200400041A (enExample)
HR (1) HRP20050798A2 (enExample)
IL (1) IL170290A (enExample)
MA (1) MA27747A1 (enExample)
MX (1) MXPA05009660A (enExample)
NL (1) NL1025710C2 (enExample)
NO (1) NO20054095L (enExample)
OA (1) OA13038A (enExample)
PA (1) PA8597501A1 (enExample)
PE (1) PE20041057A1 (enExample)
PL (1) PL378749A1 (enExample)
RS (1) RS20050692A (enExample)
TN (1) TNSN05224A1 (enExample)
TW (1) TW200502234A (enExample)
UA (1) UA78437C2 (enExample)
UY (1) UY28225A1 (enExample)
WO (1) WO2004081007A1 (enExample)
ZA (1) ZA200506373B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994726B2 (en) * 2004-05-25 2006-02-07 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
ES2372694T3 (es) * 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
WO2005082370A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
HRP20090495T1 (hr) * 2004-04-02 2009-10-31 Osi Pharmaceuticals Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
JP2008512441A (ja) * 2004-09-10 2008-04-24 ファイザー・プロダクツ・インク ピリジルオキシメチル、及びベンズイソオキサゾール・アザビシクロ誘導体を使用する、認知障害の治療方法
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
CN102405214A (zh) 2009-04-20 2012-04-04 Osi药物有限责任公司 C-吡嗪-甲胺的制备
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ,エルエルシー 副腎皮質癌を治療するためのosi−906の使用
US9394290B2 (en) * 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9980945B2 (en) 2015-01-13 2018-05-29 Vanderbilt University Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
WO2023083445A1 (en) 2021-11-10 2023-05-19 Symrise Ag Compositions comprising trpm8 agonistic cooling agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX19222A (es) 1989-01-23 1993-12-01 Pfizer Agentes ansioliticos bis-aza-biciclicos
US5167034A (en) * 1990-06-18 1992-11-24 International Business Machines Corporation Data integrity for compaction devices
US5157034A (en) 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
CA2118936A1 (en) 1991-09-25 1993-04-01 Gene M. Bright Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines
ATE185565T1 (de) 1992-06-16 1999-10-15 Pfizer Verfahren und zwischenprodukte zur herstellung von bis-aza-bicyclischen anxiolytica
US5731307A (en) 1994-09-30 1998-03-24 Pfizer, Inc. Neuroleptic 2,7-disubtituted perhydro-1h-pyrido 1, 2-A!pyrazines
CA2289574C (en) 1997-05-30 2007-04-24 Neurosearch A/S 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
PA8469101A1 (es) * 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1
SK2612001A3 (en) 1998-08-26 2001-11-06 Aventis Pharma Ltd Aza-bicycles which modulate the inhibition of cell adhesion
HK1039326A1 (zh) 1998-09-18 2002-04-19 Abbott Gmbh & Co. Kg 4氨基吡咯并嘧啶作为激酶抑制剂
HK1039325B (en) 1998-09-18 2006-02-24 Abbott Gmbh & Co. Kg 4-aminopyrrolopyrimidines as kinase inhibitors
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
HUP0202248A3 (en) 1999-03-12 2006-06-28 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
EP1177792A3 (en) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders

Also Published As

Publication number Publication date
EP1608648A1 (en) 2005-12-28
AU2004220327B2 (en) 2010-06-24
HRP20050798A2 (en) 2006-02-28
ZA200506373B (en) 2006-10-25
CA2518740A1 (en) 2004-09-23
MA27747A1 (fr) 2006-02-01
NL1025710C2 (nl) 2005-10-10
IL170290A (en) 2011-02-28
OA13038A (en) 2006-11-10
JP3910627B2 (ja) 2007-04-25
HK1085725A1 (zh) 2006-09-01
AU2004220327A1 (en) 2004-09-23
KR100767854B1 (ko) 2007-10-17
UY28225A1 (es) 2004-11-08
JP2006519830A (ja) 2006-08-31
GT200400041A (es) 2005-03-23
AP2005003390A0 (en) 2005-09-30
UA78437C2 (en) 2007-03-15
CN100389115C (zh) 2008-05-21
KR20070074667A (ko) 2007-07-12
AU2010203303A1 (en) 2010-08-12
CN1759116A (zh) 2006-04-12
BRPI0408248A (pt) 2006-03-01
KR20050113221A (ko) 2005-12-01
PA8597501A1 (es) 2005-05-24
TW200502234A (en) 2005-01-16
ECSP056011A (es) 2006-01-27
EA200501148A1 (ru) 2006-04-28
CA2518740C (en) 2011-01-11
TNSN05224A1 (fr) 2007-06-11
NL1025710A1 (nl) 2004-09-14
PL378749A1 (pl) 2006-05-15
PE20041057A1 (es) 2005-01-22
US7345038B2 (en) 2008-03-18
WO2004081007A1 (en) 2004-09-23
JP2007051155A (ja) 2007-03-01
US20050026922A1 (en) 2005-02-03
NO20054095D0 (no) 2005-09-02
RS20050692A (sr) 2007-11-15
MXPA05009660A (es) 2005-10-20
AR043537A1 (es) 2005-08-03
EP1608648B1 (en) 2012-07-18
EA009527B1 (ru) 2008-02-28

Similar Documents

Publication Publication Date Title
CY1121699T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
EA200600892A1 (ru) Новые хинолиновые производные
DE602004018617D1 (de) Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
EA200970379A1 (ru) Бициклические гетероароматические соединения
ZA200609261B (en) Fused quinoline derivative and use thereof
TW200833675A (en) Nicotinamide derivatives
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
TW200718692A (en) Dihydrobenzofuran derivatives and uses thereof
MXPA05009660A (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol.
NO20073720L (no) Heterocyklisk substituerte fenylmetanoner som inhibitorer av glycintransportorer
DE602004016123D1 (de) Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
TW200740805A (en) Novel compounds
NO20093275L (no) 1,3-Dihydroimidazol-2-thione derivater som inhibitorer av dopamin-beta-hydroksylase
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
MXPA05007494A (es) Nuevos compuestos.
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
CR20230382A (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
WO2005003087A3 (en) Oxazole derivatives as antibacterial agents
ATE453389T1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
EA200501881A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ ПИРРОЛА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ HMG-CoA
NO20051844L (no) Piperazinderivater og fremgangsmate for anvendelse derav.
NO20071230L (no) Oksazolidinoner inneholdende oksindoler som antibakterielle midler
JOP20240119A1 (ar) مشتقات نافثيريدينون لمعالجة مرض أو اضطراب